<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.biomedcentral.com/feeds/mostaccessed/journal?journal=bmcneurosci&amp;quantity=&amp;format=rss&amp;version=">
        <title>BMC Neuroscience - Most accessed articles</title>
        <link>http://www.biomedcentral.com/bmcneurosci/</link>
        <description>The most accessed research articles published by BMC Neuroscience</description>
        <dc:date>2009-11-13T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2202/10/130" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2202/10/132" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2202/10/131" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2202/10/129" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2202/10/128" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2202/10/126" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2202/10/133" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2202/10/122" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2202/6/9" />
                                <rdf:li rdf:resource="http://www.biomedcentral.com/1471-2202/10/127" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.biomedcentral.com/1471-2202/10/130">
        <title>Progranulin is expressed within motor neurons and promotes neuronal cell survival </title>
        <description>Background:
Progranulin is a secreted high molecular weight growth factor bearing seven and one half copies of the cysteine-rich granulin-epithelin motif. While inappropriate over-expression of the progranulin gene has been associated with many cancers, haploinsufficiency leads to atrophy of the frontotemporal lobes and development of a form of dementia (frontotemporal lobar degeneration with ubiquitin positive inclusions, FTLD-U) associated with the formation of ubiquitinated inclusions. Recent reports indicate that progranulin has neurotrophic effects, which, if confirmed would make progranulin the only neuroprotective growth factor that has been associated genetically with a neurological disease in humans. Preliminary studies indicated high progranulin gene expression in spinal cord motor neurons. However, it is uncertain what the role of Progranulin is in normal or diseased motor neuron function. We have investigated progranulin gene expression and subcellular localization in cultured mouse embryonic motor neurons and examined the effect of progranulin over-expression and knockdown in the NSC-34 immortalized motor neuron cell line upon proliferation and survival.
Results:
In situ hybridisation and immunohistochemical techniques revealed that the progranulin gene is highly expressed by motor neurons within the mouse spinal cord and in primary cultures of dissociated mouse embryonic spinal cord-dorsal root ganglia. Confocal microscopy coupled to immunocytochemistry together with the use of a progranulin-green fluorescent protein fusion construct revealed progranulin to be located within compartments of the secretory pathway including the Golgi apparatus. Stable transfection of the human progranulin gene into the NSC-34 motor neuron cell line stimulates the appearance of dendritic structures and provides sufficient trophic stimulus to survive serum deprivation for long periods (up to two months). This is mediated at least in part through an anti-apoptotic mechanism. Control cells, while expressing basal levels of progranulin do not survive in serum free conditions. Knockdown of progranulin expression using shRNA technology further reduced cell survival.
Conclusion:
Neurons are among the most long-lived cells in the body and are subject to low levels of toxic challenges throughout life. We have demonstrated that progranulin is abundantly expressed in motor neurons and is cytoprotective over prolonged periods when over-expressed in a neuronal cell line. This work highlights the importance of progranulin as neuroprotective growth factor and may represent a therapeutic target for neurodegenerative diseases including motor neuron disease.</description>
        <link>http://www.biomedcentral.com/1471-2202/10/130</link>
                <dc:creator>Cara Ryan</dc:creator>
                <dc:creator>David Baranowski</dc:creator>
                <dc:creator>Babykumari Chitramuthu</dc:creator>
                <dc:creator>Suneil Malik</dc:creator>
                <dc:creator>Zhi Li</dc:creator>
                <dc:creator>Mingju Cao</dc:creator>
                <dc:creator>Sandra Minotti</dc:creator>
                <dc:creator>Heather Durham</dc:creator>
                <dc:creator>Denis Kay</dc:creator>
                <dc:creator>Christopher Shaw</dc:creator>
                <dc:creator>Hugh Bennett</dc:creator>
                <dc:creator>Andrew Bateman</dc:creator>
                <dc:source>BMC Neuroscience 2009, 10:130</dc:source>
        <dc:date>2009-10-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2202-10-130</dc:identifier>
        <prism:publicationName>BMC Neuroscience</prism:publicationName>
        <prism:issn>1471-2202</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>130</prism:startingPage>
        <prism:publicationDate>2009-10-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2202/10/132">
        <title>Anti-depressant and anxiolytic like behaviors in PKCI/HINT1 knockout mice associated with elevated plasma corticosterone level 
</title>
        <description>Background:
Protein kinase C interacting protein (PKCI/HINT1) is a small protein belonging to the histidine triad (HIT) family proteins. Its brain immunoreactivity is located in neurons and neuronal processes. PKCI/HINT1 gene knockout (KO) mice display hyper-locomotion in response to D-amphetamine which is considered a positive symptom of schizophrenia in animal models. Postmortem studies identified PKCI/HINT1 as a candidate molecule for schizophrenia and bipolar disorder. We investigated the hypothesis that the PKCI/HINT1 gene may play an important role in regulating mood function in the CNS. We submitted PKCI/HINT1 KO mice and their wild type (WT) littermates to behavioral tests used to study anti-depressant, anxiety like behaviors, and goal-oriented behavior. Additionally, as many mood disorders coincide with modifications of hypothalamic-pituitary-adrenal (HPA) axis function, we assessed the HPA activity through measurement of plasma corticosterone levels.
Results:
Compared to the WT controls, KO mice exhibited less immobility in the forced swim (FST) and the tail suspension (TST) tests. Activity in the TST tended to be attenuated by acute treatment with valproate at 300 mg/kg in KO mice. The PKCI/HINT1 KO mice presented less thigmotaxis in the Morris water maze and spent progressively more time in the lit compartment in the light/dark test. In a place navigation task, KO mice exhibited enhanced acquisition and retention. Furthermore, the afternoon basal plasma corticosterone level in PKCI/HINT1 KO mice was significantly higher than in the WT.
Conclusion:
PKCI/HINT1 KO mice displayed a phenotype of behavioral and endocrine features which indicate changes of mood function, including anxiolytic-like and anti-depressant like behaviors, in conjunction with an elevated corticosterone level in plasma. These results suggest that the PKCI/HINT 1 gene could be important for the mood regulation function in the CNS.</description>
        <link>http://www.biomedcentral.com/1471-2202/10/132</link>
                <dc:creator>Elisabeth Barbier</dc:creator>
                <dc:creator>Jia Bei Wang</dc:creator>
                <dc:source>BMC Neuroscience 2009, 10:132</dc:source>
        <dc:date>2009-11-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2202-10-132</dc:identifier>
        <prism:publicationName>BMC Neuroscience</prism:publicationName>
        <prism:issn>1471-2202</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>132</prism:startingPage>
        <prism:publicationDate>2009-11-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2202/10/131">
        <title>A novel role of dendritic gap junction and mechanisms underlying its interaction with thalamocortical conductance in fast spiking inhibitory neurons</title>
        <description>Background:
Little is known about the roles of dendritic gap junctions (GJs) of inhibitory interneurons in modulating temporal properties of sensory induced responses in sensory cortices. Electrophysiological dual patch-clamp recording and computational simulation methods were used in combination to examine a novel role of GJs in sensory mediated feed-forward inhibitory responses in barrel cortex layer IV and its underlying mechanisms.
Results:
Under physiological conditions, excitatory post-junctional potentials (EPJPs) interact with thalamocortical (TC) inputs within an unprecedented few milliseconds (i.e. over 200 Hz) to enhance the firing probability and synchrony of coupled fast-spiking (FS) cells. Dendritic GJ coupling allows fourfold increase in synchrony and a significant enhancement in spike transmission efficacy in excitatory spiny stellate cells. The model revealed the following novel mechanisms: 1) rapid capacitive current (Icap) underlies the activation of voltage-gated sodium channels; 2) there was less than 2 milliseconds in which the Icap underlying TC input and EPJP was coupled effectively; 3) cells with dendritic GJs had larger input conductance and smaller membrane response to weaker inputs; 4) synchrony in inhibitory networks by GJ coupling leads to reduced sporadic lateral inhibition and increased TC transmission efficacy.
Conclusion:
Dendritic GJs of neocortical inhibitory networks can have very powerful effects in modulating the strength and the temporal properties of sensory induced feed-forward inhibitory and excitatory responses at a very high frequency band (&gt;200 Hz). Rapid capacitive currents are identified as main mechanisms underlying interaction between two transient synaptic conductances.</description>
        <link>http://www.biomedcentral.com/1471-2202/10/131</link>
                <dc:creator>Qian-Quan Sun</dc:creator>
                <dc:source>BMC Neuroscience 2009, 10:131</dc:source>
        <dc:date>2009-10-29T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2202-10-131</dc:identifier>
        <prism:publicationName>BMC Neuroscience</prism:publicationName>
        <prism:issn>1471-2202</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>131</prism:startingPage>
        <prism:publicationDate>2009-10-29T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2202/10/129">
        <title>Hypothalamic FTO is associated with the regulation of energy intake not feeding reward</title>
        <description>Background:
Polymorphism in the FTO gene is strongly associated with obesity, but little is known about the molecular bases of this relationship. We investigated whether hypothalamic FTO is involved in energy-dependent overconsumption of food. We determined FTO mRNA levels in rodent models of short- and long-term intake of palatable fat or sugar, deprivation, diet-induced increase in body weight, baseline preference for fat versus sugar as well as in same-weight animals differing in the inherent propensity to eat calories especially upon availability of diverse diets, using quantitative PCR. FTO gene expression was also studied in organotypic hypothalamic cultures treated with anorexigenic amino acid, leucine. In situ hybridization (ISH) was utilized to study FTO signal in reward- and hunger-related sites, colocalization with anorexigenic oxytocin, and c-Fos immunoreactivity in FTO cells at initiation and termination of a meal.
Results:
Deprivation upregulated FTO mRNA, while leucine downregulated it. Consumption of palatable diets or macronutrient preference did not affect FTO expression. However, the propensity to ingest more energy without an effect on body weight was associated with lower FTO mRNA levels. We found that 4-fold higher number of FTO cells displayed c-Fos at meal termination as compared to initiation in the paraventricular and arcuate nuclei of re-fed mice. Moreover, ISH showed that FTO is present mainly in hunger-related sites and it shows a high degree of colocalization with anorexigenic oxytocin.
Conclusion:
We conclude that FTO mRNA is present mainly in sites related to hunger/satiation control; changes in hypothalamic FTO expression are associated with cues related to energy intake rather than feeding reward. In line with that, neurons involved in feeding termination express FTO. Interestingly, baseline FTO expression appears linked not only with energy intake but also energy metabolism.</description>
        <link>http://www.biomedcentral.com/1471-2202/10/129</link>
                <dc:creator>Pawel Olszewski</dc:creator>
                <dc:creator>Robert Fredriksson</dc:creator>
                <dc:creator>Agnieszka Olszewska</dc:creator>
                <dc:creator>Olga Stephansson</dc:creator>
                <dc:creator>Johan Alsio</dc:creator>
                <dc:creator>Katarzyna Radomska</dc:creator>
                <dc:creator>Allen Levine</dc:creator>
                <dc:creator>Helgi Schioth</dc:creator>
                <dc:source>BMC Neuroscience 2009, 10:129</dc:source>
        <dc:date>2009-10-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2202-10-129</dc:identifier>
        <prism:publicationName>BMC Neuroscience</prism:publicationName>
        <prism:issn>1471-2202</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>129</prism:startingPage>
        <prism:publicationDate>2009-10-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2202/10/128">
        <title>Chondroitin sulfate proteoglycans regulate the growth, differentiation and migration of multipotent neural precursor cells through the integrin signaling pathway
</title>
        <description>Background:
Neural precursor cells (NPCs) are defined by their ability to proliferate, self-renew, and retain the potential to differentiate into neurons and glia. Deciphering the factors that regulate their behaviors will greatly aid in their use as potential therapeutic agents or targets. Chondroitin sulfate proteoglycans (CSPGs) are prominent components of the extracellular matrix (ECM) in the central nervous system (CNS) and are assumed to play important roles in controlling neuronal differentiation and development.
Results:
In the present study, we demonstrated that CSPGs were constitutively expressed on the NPCs isolated from the E16 rat embryonic brain. When chondroitinase ABC was used to abolish the function of endogenous CSPGs on NPCs, it induced a series of biological responses including the proliferation, differentiation and migration of NPCs, indicating that CSPGs may play a critical role in NPC development and differentiation. Finally, we provided evidence suggesting that integrin signaling pathway may be involved in the effects of CSPGs on NPCs.
Conclusion:
The present study investigating the influence and mechanisms of CSPGs on the differentiation and migration of NPCs should help us to understand the basic biology of NPCs during CNS development and provide new insights into developing new strategies for the treatment of the neurological disorders in the CNS.</description>
        <link>http://www.biomedcentral.com/1471-2202/10/128</link>
                <dc:creator>Wenli Gu</dc:creator>
                <dc:creator>Saili Fu</dc:creator>
                <dc:creator>Yanxia Wang</dc:creator>
                <dc:creator>Ying Li</dc:creator>
                <dc:creator>Hezuo Lu</dc:creator>
                <dc:creator>Xiaoming Xu</dc:creator>
                <dc:creator>Peihua Lu</dc:creator>
                <dc:source>BMC Neuroscience 2009, 10:128</dc:source>
        <dc:date>2009-10-21T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2202-10-128</dc:identifier>
        <prism:publicationName>BMC Neuroscience</prism:publicationName>
        <prism:issn>1471-2202</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>128</prism:startingPage>
        <prism:publicationDate>2009-10-21T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2202/10/126">
        <title>Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke</title>
        <description>Background:
Minocycline, a second-generation tetracycline with anti-inflammatory and anti-apoptotic properties, has been shown to promote therapeutic benefits in experimental stroke. However, equally compelling evidence demonstrates that the drug exerts variable and even detrimental effects in many neurological disease models. Assessment of the mechanism underlying minocycline neuroprotection should clarify the drug&apos;s clinical value in acute stroke setting.
Results:
Here, we demonstrate that minocycline attenuates both in vitro (oxygen glucose deprivation) and in vivo (middle cerebral artery occlusion) experimentally induced ischemic deficits by direct inhibition of apoptotic-like neuronal cell death involving the anti-apoptotic Bcl-2/cytochrome c pathway. Such anti-apoptotic effect of minocycline is seen in neurons, but not apparent in astrocytes. Our data further indicate that the neuroprotection is dose-dependent, in that only low dose minocycline inhibits neuronal cell death cascades at the acute stroke phase, whereas the high dose exacerbates the ischemic injury.
Conclusion:
The present study advises our community to proceed with caution to use the minimally invasive intravenous delivery of low dose minocycline in order to afford neuroprotection that is safe for stroke.</description>
        <link>http://www.biomedcentral.com/1471-2202/10/126</link>
                <dc:creator>Noriyuki Matsukawa</dc:creator>
                <dc:creator>Takao Yasuhara</dc:creator>
                <dc:creator>Koichi Hara</dc:creator>
                <dc:creator>Lin Xu</dc:creator>
                <dc:creator>Mina Maki</dc:creator>
                <dc:creator>Guolong Yu</dc:creator>
                <dc:creator>Yuji Kaneko</dc:creator>
                <dc:creator>Kosei Ojika</dc:creator>
                <dc:creator>David Hess</dc:creator>
                <dc:creator>Cesar Borlongan</dc:creator>
                <dc:source>BMC Neuroscience 2009, 10:126</dc:source>
        <dc:date>2009-10-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2202-10-126</dc:identifier>
        <prism:publicationName>BMC Neuroscience</prism:publicationName>
        <prism:issn>1471-2202</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>126</prism:startingPage>
        <prism:publicationDate>2009-10-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2202/10/133">
        <title>Status epilepticus affects the gigantocellular network of the pontine reticular formation</title>
        <description>Background:
The impairment of the pontine reticular formation (PRF) has recently been revealed to be histopathologically connected with focal-cortical seizure induced generalized convulsive status epilepticus. To elucidate whether the impairment of the PRF is a general phenomenon during status epilepticus, the focal-cortical 4-aminopyridine (4-AP) application was compared with other epilepsy models. The presence of &quot;dark&quot; neurons in the PRF was investigated by the sensitive silver method of Gallyas in rats sacrificed at 3 h after focal 4-AP crystal or systemic 4-AP, pilocarpine, or kainic acid application. The behavioral signs of the developing epileptic seizures were scored in all rats. The EEG activity was recorded in eight rats.
Results:
Regardless of the initiating drug or method of administration, &quot;dark&quot; neurons were consistently found in the PRF of animals entered the later phases of status epilepticus. EEG recordings demonstrated the presence of slow oscillations (1.5-2.5 Hz) simultaneously with the appearance of giant &quot;dark&quot; neurons in the PRF.
Conclusion:
We argue that the observed slow oscillation corresponds to the late periodic epileptiform discharge phase of status epilepticus, and that the PRF may be involved in the progression of status epilepticus.</description>
        <link>http://www.biomedcentral.com/1471-2202/10/133</link>
                <dc:creator>Peter Baracskay</dc:creator>
                <dc:creator>Viola Kiglics</dc:creator>
                <dc:creator>Katalin Kekesi</dc:creator>
                <dc:creator>Gabor Juhasz</dc:creator>
                <dc:creator>Andras Czurko</dc:creator>
                <dc:source>BMC Neuroscience 2009, 10:133</dc:source>
        <dc:date>2009-11-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2202-10-133</dc:identifier>
        <prism:publicationName>BMC Neuroscience</prism:publicationName>
        <prism:issn>1471-2202</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>133</prism:startingPage>
        <prism:publicationDate>2009-11-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2202/10/122">
        <title>Differentiation of neurons from neural precursors generated 
in floating spheres from embryonic stem cells 

</title>
        <description>Background:
Neural differentiation of embryonic stem (ES) cells is usually achieved by induction of ectoderm in embryoid bodies followed by the enrichment of neuronal progenitors using a variety of factors. Obtaining reproducible percentages of neural cells is difficult and the methods are time consuming.
Results:
Neural progenitors were produced from murine ES cells by a combination of nonadherent conditions and serum starvation. Conversion to neural progenitors was accompanied by downregulation of Oct4 and NANOG and increased expression of nestin. ES cells containing a GFP gene under the control of the Sox1 regulatory regions became fluorescent upon differentiation to neural progenitors, and ES cells with a tau-GFP fusion protein became fluorescent upon further differentiation to neurons. Neurons produced from these cells upregulated mature neuronal markers, or differentiated to glial and oligodendrocyte fates. The neurons gave rise to action potentials that could be recorded after application of fixed currents.
Conclusion:
Neural progenitors were produced from murine ES cells by a novel method that induced neuroectoderm cells by a combination of nonadherent conditions and serum starvation, in contrast to the embryoid body method in which neuroectoderm cells must be selected after formation of all three germ layers.</description>
        <link>http://www.biomedcentral.com/1471-2202/10/122</link>
                <dc:creator>Huawei Li</dc:creator>
                <dc:creator>Hong Liu</dc:creator>
                <dc:creator>C Corrales</dc:creator>
                <dc:creator>Jessica Risner</dc:creator>
                <dc:creator>Jeff Forrester</dc:creator>
                <dc:creator>Jeffrey Holt</dc:creator>
                <dc:creator>Stefan Heller</dc:creator>
                <dc:creator>Albert Edge</dc:creator>
                <dc:source>BMC Neuroscience 2009, 10:122</dc:source>
        <dc:date>2009-09-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2202-10-122</dc:identifier>
        <prism:publicationName>BMC Neuroscience</prism:publicationName>
        <prism:issn>1471-2202</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>122</prism:startingPage>
        <prism:publicationDate>2009-09-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2202/6/9">
        <title>Nucleus accumbens core lesions retard instrumental learning and performance with delayed reinforcement in the rat</title>
        <description>Background:
Delays between actions and their outcomes severely hinder reinforcement learning systems, but little is known of the neural mechanism by which animals overcome this problem and bridge such delays. The nucleus accumbens core (AcbC), part of the ventral striatum, is required for normal preference for a large, delayed reward over a small, immediate reward (self-controlled choice) in rats, but the reason for this is unclear. We investigated the role of the AcbC in learning a free-operant instrumental response using delayed reinforcement, performance of a previously-learned response for delayed reinforcement, and assessment of the relative magnitudes of two different rewards.
Results:
Groups of rats with excitotoxic or sham lesions of the AcbC acquired an instrumental response with different delays (0, 10, or 20 s) between the lever-press response and reinforcer delivery. A second (inactive) lever was also present, but responding on it was never reinforced. As expected, the delays retarded learning in normal rats. AcbC lesions did not hinder learning in the absence of delays, but AcbC-lesioned rats were impaired in learning when there was a delay, relative to sham-operated controls. All groups eventually acquired the response and discriminated the active lever from the inactive lever to some degree. Rats were subsequently trained to discriminate reinforcers of different magnitudes. AcbC-lesioned rats were more sensitive to differences in reinforcer magnitude than sham-operated controls, suggesting that the deficit in self-controlled choice previously observed in such rats was a consequence of reduced preference for delayed rewards relative to immediate rewards, not of reduced preference for large rewards relative to small rewards. AcbC lesions also impaired the performance of a previously-learned instrumental response in a delay-dependent fashion.
Conclusions:
These results demonstrate that the AcbC contributes to instrumental learning and performance by bridging delays between subjects&apos; actions and the ensuing outcomes that reinforce behaviour.</description>
        <link>http://www.biomedcentral.com/1471-2202/6/9</link>
                <dc:creator>Rudolf Cardinal</dc:creator>
                <dc:creator>Timothy Cheung</dc:creator>
                <dc:source>BMC Neuroscience 2005, 6:9</dc:source>
        <dc:date>2005-02-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2202-6-9</dc:identifier>
        <prism:publicationName>BMC Neuroscience</prism:publicationName>
        <prism:issn>1471-2202</prism:issn>
        <prism:volume>6</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2005-02-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.biomedcentral.com/1471-2202/10/127">
        <title>Electrophysiological evidence for an early processing of human voices</title>
        <description>Background:
Previous electrophysiological studies have identified a &quot;voice specific response&quot; (VSR) peaking around 320 ms after stimulus onset, a latency markedly longer than the 70 ms needed to discriminate living from non-living sound sources and the 150 ms to 200 ms needed for the processing of voice paralinguistic qualities. In the present study, we investigated whether an early electrophysiological difference between voice and non-voice stimuli could be observed.
Results:
ERPs were recorded from 32 healthy volunteers who listened to 200 ms long stimuli from three sound categories - voices, bird songs and environmental sounds - whilst performing a pure-tone detection task. ERP analyses revealed voice/non-voice amplitude differences emerging as early as 164 ms post stimulus onset and peaking around 200 ms on fronto-temporal (positivity) and occipital (negativity) electrodes.
Conclusion:
Our electrophysiological results suggest a rapid brain discrimination of sounds of voice, termed the &quot;fronto-temporal positivity to voices&quot; (FTPV), at latencies comparable to the well-known face-preferential N170.</description>
        <link>http://www.biomedcentral.com/1471-2202/10/127</link>
                <dc:creator>Ian Charest</dc:creator>
                <dc:creator>Cyril Pernet</dc:creator>
                <dc:creator>Guillaume Rousselet</dc:creator>
                <dc:creator>Ileana Quinones</dc:creator>
                <dc:creator>Marianne Latinus</dc:creator>
                <dc:creator>Sarah Fillion-Bilodeau</dc:creator>
                <dc:creator>Jean-Pierre Chartrand</dc:creator>
                <dc:creator>Pascal Belin</dc:creator>
                <dc:source>BMC Neuroscience 2009, 10:127</dc:source>
        <dc:date>2009-10-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1471-2202-10-127</dc:identifier>
        <prism:publicationName>BMC Neuroscience</prism:publicationName>
        <prism:issn>1471-2202</prism:issn>
        <prism:volume>10</prism:volume>
        <prism:startingPage>127</prism:startingPage>
        <prism:publicationDate>2009-10-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
